126 results on '"M. Cantarella"'
Search Results
2. The Importance of pH on the Biotransformation of Bromoxynil by Microbacterium imperiale CBS 498-74 Resting Cells
- Author
-
F. Pasquarelli, N. Chuchat, A. Spera, L. Cantarella, and M. Cantarella
- Subjects
Chemical engineering ,TP155-156 ,Computer engineering. Computer hardware ,TK7885-7895 - Abstract
This work enlarges our previous results (Pasquarelli et al., 2015) on the effect of pH on the bioconversion of 3,5-dibromo-4-hydroxybenzonitrile (bromoxynil) using Microbacterium imperiale CBS 498-74 resting cells. Their sequential enzymes, nitrile hydratase and amidase, which operate in cascade, transform the nitrile into the corresponding acid, via an amide as intermediate. This paper highlights the influence of different pH on the kinetic parameters, Vmax and KM, the stability of the enzymes and the completeness of bromoxynil bioconversion in batch reactors. Results from continuous stirred UF-membrane reactors (CSMR) suggest, for real application and high conversion yield (near 75% for more than 180 h continuous process), to operate at pH 6.5 realising the best compromise between enzyme stability, high Vmax. This even if at pH 7.0 the enzyme half life is higher.
- Published
- 2016
- Full Text
- View/download PDF
3. Enhancing the photocatalytic properties of doped TiO2 nanowires grown by seed-assisted thermal oxidation
- Author
-
F. Giuffrida, L. Calcagno, A.A. Leonardi, M Cantarella, M. Zimbone, and G. Impellizzeri
- Subjects
Materials Chemistry ,Metals and Alloys ,Surfaces and Interfaces ,Surfaces, Coatings and Films ,Electronic, Optical and Magnetic Materials - Published
- 2023
4. [18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer
- Author
-
Lorenzo Di Cesare Mannelli, Gabriele Coraggio, S. Montrone, Serena Chiacchio, Roberta Zanca, Sergio Ricci, A. Gonnelli, Martina Sollini, Davide Baldaccini, Francesco Pasqualetti, M. Cantarella, P. Cocuzza, Valentina Mazzotti, Andrea Sbrana, Riccardo Morganti, Paola Anna Erba, A. Molinari, Aldo Sainato, Luca Galli, Marco Panichi, Fabiola Paiar, Andrea Marciano, Pasqualetti, F, Panichi, M, Sollini, M, Sainato, A, Galli, L, Morganti, R, Chiacchio, S, Marciano, A, Zanca, R, Mannelli, L, Coraggio, G, Sbrana, A, Cocuzza, P, Montrone, S, Baldaccini, D, Gonnelli, A, Molinari, A, Cantarella, M, Mazzotti, V, Ricci, S, Paiar, F, and Erba, P
- Subjects
Biochemical recurrence ,medicine.medical_specialty ,Stereotactic body radiotherapy ,medicine.medical_treatment ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Prostate ,medicine ,Clinical endpoint ,Radiology, Nuclear Medicine and imaging ,Prospective cohort study ,Survival analysis ,PET-CT ,F]FMCH PET/CT ,Chemistry ,General Medicine ,medicine.disease ,Radiation therapy ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Radiology ,[ ,18 - Abstract
Background In the last years, functional imaging has given a significant contribution to the clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present a prospective study aiming to validate the role of [18F]Fluoro-Methyl Choline ([18F]FMCH) PET/CT in the selection of PCa patients suitable for stereotactic body radiotherapy (SBRT). Methods Patients with biochemical recurrence limited up to three lesions revealed by [18F]FMCH PET/CT were enrolled in the present study and treated with SBRT on all active lesions. Systemic therapy-free survival since the [18F]FMCH PET/CT was considered as the primary endpoint. Results Forty-six patients were evaluated, and a total of 67 lesions were treated. After a median follow-up of 28.9 months, systemic therapy was started in 30 patients (65.2%) and median systemic therapy-free survival was 39.1 months (95% CI 6.5–68.6); 6, 12, and 24-month ratios were 93.5%, 73.9%, and 63.1%, respectively. At univariate Cox regression analysis, Delta PSA demonstrated an impact on systemic therapy-free survival (p Conclusions Based on our findings, [18F]FMCH PET/CT can identify oligometastatic prostate cancer patients suitable for SBRT, resulting in a systemic therapy-free survival of 39.1 months.
- Published
- 2019
5. Impact of recurrence pattern in patients undergoing a second surgery for recurrent glioblastoma
- Author
-
Orazio Santonocito, Isacco Desideri, Cristian Scatena, Nicola Montemurro, A. Gonnelli, Francesco Pasqualetti, Antonio Giuseppe Naccarato, Paolo Perrini, Noemi Giannini, S. Montrone, Giovanni Gadducci, Riccardo Morganti, Fabiola Paiar, Giulia Malfatti, M. Cantarella, L. Visani, Carlo Gambacciani, and Mauro Loi
- Subjects
medicine.medical_specialty ,Neurology ,Pattern of failure ,Cohort Studies ,Recurrent glioblastoma ,medicine ,Humans ,In patient ,Prospective Studies ,Prospective cohort study ,Survival analysis ,Neuroradiology ,Retrospective Studies ,business.industry ,Brain Neoplasms ,General Medicine ,University hospital ,medicine.disease ,Glioblastoma ,Second surgery ,Surgery ,Neurology (clinical) ,Neoplasm Recurrence, Local ,business - Abstract
Background. The impact of different patterns of glioblastoma (GBM) recurrence has not yet been fully established in patients suitable for a second surgery. Through the present observational study carried out at Pisa University Hospital, we aimed to examine the impact of different patterns of GBM failure on patients’ survival and second surgery outcomes.Methods. Overall survival was assessed according to clinical characteristics, including pattern of recurrence, in a prospective cohort of recurrent GBM patients. Survival curves were calculated using the Kaplan-Meier method and the log-rank test was applied to evaluate the differences between curves.Results. Contact with ventricles, a second surgery and meningeal spread had a statistically impact on patient survival after the diagnosis of GBM recurrence (P=0.032, P=0.019 and PConclusions. The local recurrence pattern could be a promising field of interest for patients with recurrent GBM suitable for a second surgery.
- Published
- 2021
6. Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy
- Author
-
Teresa Di Desidero, Guido Bocci, Antonio Giuseppe Naccarato, M. Cantarella, Katia Zavaglia, Riccardo Morganti, Paola Orlandi, S. Montrone, Durim Delishaj, Francesco Carbone, Francesco Pasqualetti, Chiara Maria Mazzanti, A. Gonnelli, Sara Franceschi, Stefano Ursino, Fabiola Paiar, Valerio Ortenzi, and A. Molinari
- Subjects
Adult ,Male ,rs1695 ,0301 basic medicine ,Oncology ,medicine.medical_specialty ,Multivariate analysis ,Single-nucleotide polymorphism ,Bioinformatics ,Polymorphism, Single Nucleotide ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Chemotherapy ,Pharmacology (medical) ,Progression-free survival ,Prospective cohort study ,Genetic Association Studies ,Survival analysis ,Aged ,Aged, 80 and over ,Pharmacology ,Temozolomide ,Radiotherapy ,Proportional hazards model ,business.industry ,Chemoradiotherapy ,Middle Aged ,Survival Analysis ,GSTP-1 ,Single nucleotide polymorphism ,030104 developmental biology ,Glutathione S-Transferase pi ,030220 oncology & carcinogenesis ,Multivariate Analysis ,Female ,Glioblastoma ,business ,Pharmacogenetics ,medicine.drug - Abstract
Glioblastoma (GBM) is the most frequent malignant primary brain tumor in adults and, despite recent advances, the prognosis for this cancer remains dismal. The aims of this study were to test the influence of XRCC1 rs25487, XRCC3 rs861539, XRCC3 rs1799794, RAD51 rs1801320 and GSTP-1 rs1695 single nucleotide polymorphisms on progression free survival (PFS) and overall survival (OS) in GBM patients treated with radiotherapy (RT) and temozolomide (TMZ). Fifty GBM patients treated with upfront radio-chemotherapy (RT 60 Gy/30 sessions; TMZ 75 mg/m2 during RT and 200 mg/m2 days 1 → 5 every 28 days) were enrolled. Survival curves were calculated using the Kaplan-Meier method, and the log-rank test was used to evaluate differences between curves. A trend to a statistically significant association with PFS in univariate and multivariate COX regression analysis was found with GSTP-1 rs1695 polymorphism (p = 0.087 and p = 0.097 on univariate and multivariate analyses, respectively). Conversely, the same GSTP-1 rs1695 SNP revealed a statistically significant association with OS (p = 0.007 and p = 0.042 on univariate and multivariate analysis, respectively). Our pharmacogenetic prospective study suggests that GSTP-1 rs1695 genotypes can be associated with different OS in GBM patients treated with RT and TMZ.
- Published
- 2017
7. A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?
- Author
-
Andrea Pace, Luisa Bellu, Stefano Telera, Antonio Tanzilli, Alessandra Fabi, Fabiola Paiar, Giuseppe Lombardi, M. Cantarella, A. Gonnelli, Carmine M. Carapella, Francesco Pasqualetti, Francesco Cognetti, Irene Terrenato, Antonello Vidiri, A. Molinari, Veronica Villani, Marta Maschio, Mariantonia Carosi, and Vittorina Zagonel
- Subjects
0301 basic medicine ,Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Bevacizumab ,Adolescent ,medicine.drug_class ,Improved survival ,Kaplan-Meier Estimate ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Antineoplastic Agents, Immunological ,Internal medicine ,Glioma ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Odds Ratio ,Humans ,In patient ,Aged ,Retrospective Studies ,Aged, 80 and over ,End point ,Karnofsky Performance Status ,business.industry ,bevacizumab ,clinical benefit ,glioma ,Retrospective cohort study ,General Medicine ,Middle Aged ,medicine.disease ,030104 developmental biology ,Treatment Outcome ,030220 oncology & carcinogenesis ,Retreatment ,Corticosteroid ,Female ,business ,medicine.drug - Abstract
Aim: This multicenter, retrospective study evaluates the clinical benefit (CB) of bevacizumab, alone or in combination, in recurrent gliomas (RG). Patients & methods: The CB was measured as a reduction of corticosteroid dosage and an improvement ≥20 points in the Karnofsky Performance Status lasting ≥3 months. Results: We collected data of 197 RG patients. A CB was observed in 120, patients without significant differences between patients treated with bevacizumab alone or in combination. The rate of patients who achieved a CB and free from progression at 1 year was 21.5 versus 1.4% in patients who did not report CB. Conclusion: The majority of RG patients treated with bevacizumab reported CB. Moreover, patients with CB showed improved survival.
- Published
- 2019
8. P01.127 The impact of first MR in clinical decision making of patients with high grade glioma treated with radio-chemotherapy
- Author
-
M. Cosottini, Fabiola Paiar, M. Cantarella, A. Gonnelli, A. Molinari, and Francesco Pasqualetti
- Subjects
Cancer Research ,medicine.medical_specialty ,Temozolomide ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Salvage therapy ,Magnetic resonance imaging ,medicine.disease ,Radiation therapy ,Poster Presentations ,Oncology ,Clinical decision making ,Glioma ,Medicine ,Neurology (clinical) ,Radiology ,business ,medicine.drug ,Radio chemotherapy ,High-Grade Glioma - Abstract
BACKGROUND: Standard up-front therapy of high grade glioma (HGG) is focused on the so called Stupp protocol, that includes surgical resection followed by radiotherapy (RT) combined with concomitant and adjuvant chemotherapy with temozolomide (TMZ). As supported by several international guidelines, disease assessment is performed using magnetic resonance (MR) one month since the end of RT and then every 3 months: in case of tumour progression the administration of temozolomide (the most active agent against glioma) is interrupted and salvage therapy or best supportive care are recommended. The aim of this study is to investigate in a retrospective manner the real value of first MR following RT and its relevance in clinical decision making about up-front therapy. MATERIAL AND METHODS: Between April 2005 and July 2017, data of 78 patients (pts) with a proven diagnosis of HGG and treated with Stupp protocol at the University Hospital of Pisa were collected. Tumor progression was defined according to Mac-Donald’s Criteria. Considering the potential presence of pseudo-progression (PSP) and the evolutionary pattern of the suspected recurrences, lesions suggestive for tumor progression inside the radiotherapy field were investigate with a new MR after 6–8 weeks. Otherwise, the presence of new lesions outside the radiotherapy field was interpreted as disease progression (PD) and patient’s therapy was changed. Presence or absence of symptoms, extent of surgery and MGMT methylation status were recorded. RESULTS: The first MR after RT-CT evidenced infield progression (interpreted as PSP) in 16 pts (20,5%) and outfield progression in 8 (10.2%).Three out of 8 patients with outfield progression were symptomatic for the tumor growth. The second MRI confirmed the presence of PSP in 10 pts out of 16 pts whereas in 6 patients a true progression (PD) was present since the first MR. CONCLUSION: In absence of symptoms, the first MR after radio-chemotherapy influenced clinical decision making (sending the patients to further salvage therapy or BSC) only in 5 out of 78 patients (6.4%). In 72 patients, even in presence of radiological signs suggestive for disease progression inside the RT field, clinical decision making did not change. Further studies involving a higher number of patients are required in order to confirm our findings.
- Published
- 2018
9. P01.116 Treatment with Dabrafenib in a patient with BRAF mutated recurrent ganglioglioma
- Author
-
Roberta Rudà, Roberto Mattioni, D. Baldaccini, M. Cantarella, A. Molinari, Fabiola Paiar, M Grazzini, Riccardo Soffietti, Francesco Pasqualetti, and A. Gonnelli
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Patient care team ,Temozolomide ,Proximal isovelocity surface area ,business.industry ,Disease progression ,Dabrafenib ,medicine.disease ,Ganglioglioma ,Tumor excision ,Poster Presentations ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Internal medicine ,medicine ,Neurology (clinical) ,Progression-free survival ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
BACKGROUND: Gangliogliomas are rare tumor usually arising in the supratentorial region, WHO grade 1 or 2. In these tumors, BRAF mutation may constitute a driver genetic alteration and a biomarker of response to BRAF inhibitors. Dabrafenib is an oral inhibitor of BRAF and has shown to significantly improve progression-free survival in patients with BRAF mutated metastatic melanoma. MATERIALS AND METHODS: In March 2015, after being diagnosed with left front-temporal enhancing mass, a 31-year-old lady was referred to the University Hospital of Pisa. In the previous two months, the patient had noticed motor aphasia and, due to the persistence of the symptoms, she was sent to the emergency room by the general practitioner. Previous history did not show any co-morbidity. An MRI displayed a fronto-parietal tumor with some contrast enhancement. The patient underwent craniotomy and subtotal tumor resection. Histopathology revealed a WHO grade I ganglioglioma and immunohistochemistry (IHC) documented focal expression of P-53, CD34, and ki-67 proliferation index of 3%. BRAF V600E mutation (Val600Glu(GTG◊GAG)) was detected by polymerase chain reaction. Postoperatively, the patient received radio-chemotherapy with temozolomide (60 Gy in 30 fractions), but 10 months later the patient experienced disease progression. A second surgery was performed without any neurological impairment. The disease monitoring with MRI revealed a partial tumor removal and the pathology confirmed the previous diagnosis. After second surgery, considering the Karnofsky Performance Status Score of 100, the young age and, the presence of BRAF mutation, our multidisciplinary team (in agreement with colleagues of the Neuro-Oncology Unit of the University of Turin) decided to administer the selective BRAF inhibitor Dabrafenib (75 mg twice per day for the first 21 days, then 150 mg twice per day). Since the beginning of the salvage systemic therapy, the patient did not experience treatment-related adverse events. Magnetic resonance performed two months after the start of Dabrafenib and then every three months showed a major response. After 15 months due to the persistent disease response and MRI, we decided to stop the administration of Dabrafenib. Three months after interruption of dabrafenib a new MRI detected a second disease progression being the patient asymptomatic, and we decided to restart the administration of Dabrafenib, which is ongoing. CONCLUSION: Despite the lack of literature on the use of Dabrafenib in Central Nervous System tumors, this case report provides evidence that Dabrafenib can be active in patients with ganglioglioma with BRAF mutation and confirms the safety related to this agent.
- Published
- 2018
10. Salvage Hypofractionated Radiotherapy in Combination with Bevacizumab in Patients with Recurrent High Grade Glioma: A Mono-institutional Experience
- Author
-
M. Cantarella, Durim Delishaj, Francesco Pasqualetti, A. Molinari, Mirco Cosottini, Stefano Ursino, Maria Grazia Fabrini, Fabiola Paiar, and A. Gonnelli
- Subjects
Hypofractionated Radiotherapy ,Cancer Research ,medicine.medical_specialty ,Bevacizumab ,salvage surgery ,business.industry ,salvage stereotactic radiotherapy ,glioblastoma ,Recurrent high glioma ,bevacizumab ,medicine.disease ,concomitant therapies ,Oncology ,Medicine ,In patient ,Salvage surgery ,Radiology ,Recurrent high glioma, salvage stereotactic radiotherapy, bevacizumab, concomitant therapies, salvage surgery, glioblastoma ,General Pharmacology, Toxicology and Pharmaceutics ,business ,medicine.drug ,High-Grade Glioma ,Glioblastoma - Published
- 2018
11. Different timing to use bevacizumab in patients with recurrent glioblastoma: Early versus delayed administration
- Author
-
Francesco Pasqualetti, Roberta Rudà, P. Cocuzza, Davide Baldaccini, Fabiola Paiar, Riccardo Morganti, Giuseppe Lombardi, Durim Delishaj, Riccardo Soffietti, S. Montrone, A. Molinari, Roberto Mattioni, Valentina Mazzotti, Agostino Cristaudo, A. Gonnelli, M. Cantarella, and Maria Grazia Fabrini
- Subjects
0301 basic medicine ,Oncology ,Male ,medicine.medical_specialty ,Cancer Research ,Time Factors ,Bevacizumab ,Early administration ,Delayed administration ,Angiogenesis Inhibitors ,010501 environmental sciences ,01 natural sciences ,Time-to-Treatment ,03 medical and health sciences ,Internal medicine ,medicine ,Recurrent glioblastoma ,Humans ,In patient ,Prospective Studies ,Prospective cohort study ,Survival rate ,0105 earth and related environmental sciences ,Retrospective Studies ,business.industry ,Brain Neoplasms ,Female ,Follow-Up Studies ,Glioblastoma ,Middle Aged ,Prognosis ,Survival Rate ,Retrospective cohort study ,General Medicine ,medicine.disease ,030104 developmental biology ,Median time ,business ,medicine.drug - Abstract
Background/aim In patients with recurrent glioblastoma, the best timing to administer bevacizumab is not well addressed yet. In this study, we reported the results of a monocentric experience comparing the early use of bevacizumab (following the first GBM recurrence) with the delayed administration (following the second or even further GBM recurrences). Materials and methods This analysis included 129 glioblastoma patients with a median follow-up of 22.4 months (range=5.26-192 months). Results The median time lapse from diagnosis of glioblastoma to disease recurrence was 11.6 months; 13.1 for patients treated with deferred administration of bevacizumab and 9.9 for patients with early administration (p=0.047). Bevacizumab progression-free survival with early and delayed use was 3.45 and 2.92 months, respectively (p=0.504). Survival time from the start of bevacizumab was 6.18 months in patients with early administration, and 6.47 in the delayed administration one (p=0.318). Conclusion Delayed administration of bevacizumab can be considered in selected patients with less aggressive recurrent glioblastoma.
- Published
- 2018
12. Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy
- Author
-
Andrea Sechi, Vittorio Simeon, A. Gonnelli, Daniela Giuliani, M. Cantarella, Guido Bocci, Durim Delishaj, Francesco Pasqualetti, Marc Sanson, Teresa Di Desidero, Vittorina Zagonel, Salvatore Guarini, Giuseppe Lombardi, Romano Danesi, Paola Orlandi, Fabiola Paiar, Pasqualetti, Francesco, Orlandi, Paola, Simeon, Vittorio, Cantarella, Martina, Giuliani, Daniela, Di Desidero, Teresa, Gonnelli, Alessandra, Delishaj, Durim, Lombardi, Giuseppe, Sechi, Andrea, Sanson, Marc, Zagonel, Vittorina, Paiar, Fabiola, Danesi, Romano, Guarini, Salvatore, and Bocci, Guido
- Subjects
0301 basic medicine ,Oncology ,Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Neuroscience (miscellaneous) ,Single-nucleotide polymorphism ,Biology ,Bioinformatics ,Polymorphism, Single Nucleotide ,03 medical and health sciences ,Young Adult ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,Internal medicine ,Genotype ,medicine ,Temozolomide ,Humans ,Polymorphism ,Aged ,Retrospective Studies ,Aged, 80 and over ,Chemotherapy ,Glioblastoma ,Melanocortin receptor-4 ,Radiotherapy ,Brain Neoplasms ,Chemoradiotherapy ,Middle Aged ,Prognosis ,Radiation therapy ,Clinical trial ,Survival Rate ,030104 developmental biology ,Treatment Outcome ,Neurology ,030220 oncology & carcinogenesis ,Concomitant ,Receptor, Melanocortin, Type 4 ,Female ,Pharmacogenetics ,medicine.drug - Abstract
Melanocortins are peptides with well-recognized antiinflammatory and neuroprotective activity. No data are currently available on melanocortin receptor-4 (MC4R) gene polymorphisms and tumors, including glioblastomas (GBMs), or their relationship with radiotherapy or chemotherapy. The aim of this study was to evaluate the possible predictive/prognostic role of the MC4R SNPs on GBM patients. Fifty-five patients with a proven diagnosis of GBM, treated with radiotherapy and temozolomide, were consecutively enrolled. MC4R gene SNPs (rs17782313, rs489693, rs8087522, rs17700633) were analyzed by a validated TaqMan® SNP genotyping assays. Univariate and multivariate analyses were performed. A P
- Published
- 2018
13. Image-guided Stereotactic Body Radiotherapy in Metastatic Prostate Cancer
- Author
-
Riccardo Morganti, Fabiola Paiar, Stefano Ursino, Marco Panichi, P. Cocuzza, S. Montrone, Paola Anna Erba, Andrea Bruschi, Elisa Notini, S. Barbiero, A. Molinari, Davide Baldaccini, Valentina Mazzotti, Aldo Sainato, A. Gonnelli, M. Cantarella, Gabriele Coraggio, Francesco Pasqualetti, Pasqualetti, F, Panichi, M, Sainato, A, Baldaccini, D, Cocuzza, P, Gonnelli, A, Montrone, S, Molinari, A, Barbiero, S, Bruschi, A, Notini, E, Ursino, S, Mazzotti, V, Morganti, R, Coraggio, G, Cantarella, M, Erba, P, and Paiar, F
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Metastatic lesions ,Kaplan-Meier Estimate ,Radiosurgery ,image guided radiotherapy ,030218 nuclear medicine & medical imaging ,Stereotactic radiotherapy ,03 medical and health sciences ,Prostate cancer ,Metastatic prostate cancer ,0302 clinical medicine ,Oligometastatic patient ,medicine ,Humans ,In patient ,Prospective Studies ,Aged ,Proportional Hazards Models ,business.industry ,Radiation field ,Prostatic Neoplasms ,General Medicine ,Middle Aged ,medicine.disease ,Single fraction ,oligometastatic patients ,stereotactic body radiotherapy ,Oncology ,030220 oncology & carcinogenesis ,Observational study ,Radiology ,Neoplasm Recurrence, Local ,business ,Stereotactic body radiotherapy ,Radiotherapy, Image-Guided - Abstract
Background/aim In the last years, the use of Image Guided Stereotactic Radiotherapy (IG-SBRT) in patients with metastatic prostate cancer has increased. In this study, we aimed to assess the role of IG-SBRT in terms of local control and safety in patients with metastatic prostate cancer. Materials and methods Primary and secondary endpoints of this prospective observational study were local control and safety related to IG-SBRT. All lesions were treated with 24 Gy as a single fraction or 27 Gy in 3 fractions. After SBRT, Systemic therapies were administered only after the occurrence of more than three synchronous active lesions in oligometastatic patients (patients with less than 4 active synchronous lesions) or new lesions occurrence in patients with more than 3 synchronous lesions. Results From April 2011 to June 2017, 78 metastatic lesions (32 bone and 46 node) from 51 patients with prostate cancer were treated. After a median follow-up of 18.5 months (range=3-103 months), only 2 lesions (4%) relapsed inside the radiation field. All local recurrences were located on the bone. Estimated 12 and 24 months local control ratios were 98.7 and 97.4%, respectively. Except for one case, toxicity greater than G2 was not recorded. Conclusion IG-SBRT is safe and can be considered as a valid therapy in patients with metastatic prostate cancer requiring a long-lasting metastases control.
- Published
- 2018
14. SELECTIVE REMOVAL OF WATER CONTAMINANTS BY MOLECU-LARLY IMPRINTED POLYMER
- Author
-
M. Cantarella, S. Carroccio, S. Dattilo, C. Puglisi, and V. Privitera
- Subjects
BY MOLECULARLY IMPRINTED POLYMER ,macromolecular substances - Abstract
We propose molecularly imprinted polymers (MIPs) as valid tools for the selective removal from water of these drugs. MIPs are synthesized by copolymerization of cross-linking and function-al monomers in the presence of a target analyte, which acts as a molecular template. Following the polymerization, the template is removed to leave cavities with selectivity for the analyte, allowing the polymer to rebind the analyte with a very high specificity.
- Published
- 2018
15. EP-1227 The impact of first MR in clinical decision making of patients with HGG treated with RTCT
- Author
-
Francesco Pasqualetti, Fabiola Paiar, M. Cantarella, A. Molinari, and A. Gonnelli
- Subjects
Oncology ,medicine.medical_specialty ,Clinical decision making ,business.industry ,Internal medicine ,medicine ,Radiology, Nuclear Medicine and imaging ,Hematology ,business - Published
- 2019
16. P01.26 rs489693 Melacortin receptor gene polymorphism is associated with the progression-free survival of glioblastoma patients treated with concomitant radio-chemotherapy
- Author
-
A. Molinari, Paola Orlandi, Guido Bocci, M. Cantarella, Vittorio Simeon, Giuseppe Lombardi, A. Gonnelli, Francesco Pasqualetti, Fabiola Paiar, and T. Di Desiderio
- Subjects
Cancer Research ,Temozolomide ,business.industry ,medicine.medical_treatment ,medicine.disease ,Radiation therapy ,Oncology ,Glioma ,Concomitant ,Cancer research ,Medicine ,Neurology (clinical) ,Gene polymorphism ,Progression-free survival ,business ,Receptor ,Pharmacogenetics ,POSTER PRESENTATIONS ,medicine.drug - Abstract
Background: Glioblastoma (GBM) accounts for approximately 50% of all glioma and among these tumors, are the most malignant. The current standard of care for patients with newly diagnosed GBM includes temozolomide and radiotherapy. Melanocortins are peptides with well-recognized anti-inflammatory and neuroprotective activity. No data are currently available on MC4R gene polymorphisms and gliomas or their relationship with radiotherapy or chemotherapy. Given the association of MC4R with antiinflammatory activity, neuroprotection, induction of neural stem/progenitor cell proliferation in brain hypoxia, and prevention of astrocyte apoptosis, the aim of this study was to retrospectively evaluate the possible prognostic/predictive role of the MC4R SNPs on GBM therapy. Methods: Sixty-one patients with a proven diagnosis of GBM, ECOG PS 0–2, age greater than18 years, and treated with radiotherapy and temozolomide were enrolled. Blood samples (3 ml) were collected in EDTA tubes and stored at -80°C. Genomic DNA was extracted using QIAamp DNA Blood Mini Kit. MC4R gene SNPs (rs17782313, rs489693, rs8087522, rs17700633) were analyzed; the allelic discrimination was performed using an ABI PRISM 7900 SDS and with validated TaqMan® SNP genotyping assays. PCR reactions were carried out according to the manufacturer’s protocol. Kaplan Meier curves were performed for statistical association with genotypes. A P value less than 0.0125 (Bonferroni’s correction) was considered significant. Results: Fifty-six patients were clinically evaluated. The median progression-free survival (PFS) and median overall survival (OS) were 10.8 months and 23 months, respectively. The distribution of genotypes in the 56 patients did not deviate from Hardy-Weinberg equilibrium. A relevant finding of our study was the identification of a MC4R genotype that was significantly associated with PFS. Indeed, with regard to PFS, patients harbouring the rs489693 AA genotype had a median PFS of 3 months whereas patients with AC/CC genotypes had a median PFS of 13.7 months (P=0.0088). Interestingly, the rs489693 AA patients also had a lower median OS, even though the difference was not sta[[Unsupported Character - Codename ]]tistically significant as compared with the median OS of the AC/CC genotypes (15.6 vs. 24.6 months, respectively, P=0.274). No significant differences in PFS and OS for the other genotypes of the investigated MC4R polymorphisms were found. Conclusion: The rs489693 AA genotype is significantly associated with a shorter PFS in GBM patients treated with radiotherapy and temozolomide schedule. The present pharmacogenetic, retrospective, pilot study may represent the stimulus to prospectively investigate the role of rs489693 MC4R polymorphism as a predictive pharmacogenetic marker of GBM radio-chemotherapy.
- Published
- 2017
17. P09.41 Single agent Bevacizumab in recurrent glioblastoma after a second line chemotherapy with Fotemustine. The Italian Association of Neuro Oncology experience
- Author
-
Roberta Rudà, Alessandra Fabi, Fabiola Paiar, Riccardo Soffietti, Giuseppe Lombardi, M. Cantarella, Andrea Pace, A. Gonnelli, G. Villani, Maria Grazia Fabrini, A. Molinari, and Francesco Pasqualetti
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Bevacizumab ,business.industry ,Recurrent glioblastoma ,Neuro oncology ,Second line chemotherapy ,Internal medicine ,medicine ,Fotemustine ,Single agent ,Neurology (clinical) ,business ,POSTER PRESENTATIONS ,medicine.drug - Abstract
Bevacizumab is an anti-VEGF antibody used in the treatment of recurrent glioblastoma (GBM). Despite the available literature, few is known about the best schedule to administer this angiogenesis inhibitor: i) early, at the first recurrence, or ii) later, after a second line of chemotherapy. In this retrospective multicenter study, we reported the results obtained in 51 patients (pts) with recurrent GBM treated with single agent bevacizumab after the failure of a second-line chemotherapy with fotemustine (FTM). In March 2016, at the time of data analysis, 3 patients (5.9%) were still alive with stable disease, whereas 48 patients were dead due to disease progression. Kaplan-Meier estimated median survival from diagnosis of GBM was 28 months (95%CI 22.1-33.9). The median survival measured from the beginning of FTM and bevacizumab therapy were 11.3 (95% CI 8.4-13.6) and 6 (95% CI 3.8-8.1) months, respectively. Six and 12-month PFS rate from the beginning of bevacizumab treatment were 18% and 13%, respectively. Despite the interpretation of this study is limited by the retrospective design, bevacizumab may be a promising approach after failure of second-line FTM therapy.
- Published
- 2017
18. Clinical Outcomes of Stereotactic Body Radiotherapy in Oligometastatic Gynecological Cancer
- Author
-
M. Cantarella, Concetta Laliscia, Roberta Tana, Carlo Greco, Maria Grazia Fabrini, Durim Delishaj, Fabiola Paiar, Angiolo Gadducci, and Riccardo Morganti
- Subjects
medicine.medical_specialty ,Nausea ,Genital Neoplasms, Female ,Radiosurgery ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Positron Emission Tomography Computed Tomography ,80 and over ,medicine ,Humans ,Aged ,Aged, 80 and over ,Female ,Middle Aged ,Neoplasm Metastasis ,Retrospective Studies ,Treatment Outcome ,Adverse effect ,medicine.diagnostic_test ,business.industry ,Truebeam ,Obstetrics and Gynecology ,Retrospective cohort study ,medicine.disease ,Regimen ,Oncology ,Positron emission tomography ,030220 oncology & carcinogenesis ,Vomiting ,Radiology ,Genital Neoplasms ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Progressive disease - Abstract
ObjectiveThe objective of this study was to assess the role of stereotactic body radiotherapy (SBRT) in the treatment of distantly recurrent, oligometastatic gynecological cancer.MethodsThe hospital records of 45 patients with18F-fluorodeoxyglucose (18F-FDG) positron emission tomography positive, distantly recurrent, oligometastatic gynecological cancer were reviewed. All these patients had a number of target lesions less than 5, with largest diameter less than 6 cm. The treatment was delivered with a TrueBeam LINAC and RapidArc technique, using 10 or 6 MV FFF beams. A total of 70 lesions were treated, and lymph nodes represented the most common site of metastases, followed by lung, liver, and soft tissues. Twenty lesions were treated with one single fraction of 24 Gy and 5 lesions received 27 Gy delivered in 3 fractions, depending on the ability to fulfill adequate target coverage and safe dose/volume constraints for the organ at risk with either regimen.ResultsPositron emission tomography scan 3 months after SBRT showed a complete response (CR) in 45 lesions (64.3%), a partial response in 14 (20.0%), a stable disease in 5 (7.1%), and a progressive disease in 6 (8.6%). No lesions in CR after SBRT subsequently progressed. Overall acute toxicity occurred in 13 (28.9%) patients. The most common grade 1 to 2 adverse event was pain (n = 9, 20.0%), followed by nausea and vomiting (n = 5, 11.1%). No grade 3 to 4 acute toxicities occurred, and no late toxicities were observed. Patients who failed to achieve a CR had a 2.37-fold higher risk of progression and a 3.60-fold higher risk of death compared with complete responders (P= 0.04 andP= 0.03, respectively).ConclusionsStereotactic body radiotherapy offers an effective and safe approach for selected cases of oligometastatic gynecological cancer.
- Published
- 2017
19. P01.141 Different timing to use bevacizumab in patients with recurrent glioblastoma: early versus delayed administration
- Author
-
M. Cantarella, Roberto Mattioni, S. Montrone, Maria Grazia Fabrini, A. Gonnelli, Francesco Pasqualetti, A. Molinari, Fabiola Paiar, and D. Baldaccini
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Univariate analysis ,Temozolomide ,Bevacizumab ,business.industry ,Recurrent glioblastoma ,Malignant brain tumor ,O-6-methylguanine-DNA methyltransferase ,medicine.disease ,Poster Presentations ,Internal medicine ,Medicine ,In patient ,Neurology (clinical) ,business ,medicine.drug ,Glioblastoma - Abstract
BACKGROUND: Glioblastoma (GBM) is the most baleful malignant brain tumor in adults. After a diagnosis of relapsed GBM, multimodality salvage treatment are not incisive enough to improve overall survival (OS) beyond a few months, and their best use and the timing is not well established. Bevacizumab (BEV) seems to improve OS. The best timing for BEV administration requires further investigation. We report the results of a monocentric experience comparing the early use of BEV with delayed administration. MATERIAL AND METHODS: Data was collected from September 2008 from pts who met the following criteria:0>18years, a pathologically-confirmed diagnosis of GBM, disease recurrence after up-front RT-CT or alone CT with TMZ, KPS >60, and administration of BEV with or without concomitant CT. Single agent BEV was administered at the time of the first recurrence (early administration) after standard up-front treatment, or at the time of disease progression following a second or even further advanced line of CT (late administration). BEV response and progression were assessed using RANO criteria. Disease assessment was performed every 2 months following the start of BEV, using MRI with a contrast agent, or at the onset of symptoms. RESULTS: This analysis includes 129 pts from September 2008 to July 2017 treated with BEV for recurrent GBM. 51 pts received early administration of BEV and 77 delayed administration. The median age at the beginning of BEV was 56.4 years, MGMT methylation status was assessed in 52 pts, and clinical benefit due to BEV in 47. Median KPS at the time of BEV first administration was 80 (range 60–100). At a median follow-up of 22.4 months (range 5.26–19.2), the median lapse from diagnosis of GBM to disease recurrence was 11.6 months; 13.1 for pts treated with deferred administration of BEV and 11.1 for pts with early administration (P=0.047). Median OS in pts treated with early BEV was 19.5 months, and in pts treated with delayed BEV it was 26.7 months (P=0.040). PFS with early and delayed use of BEV was 3.45 and 2.92 months, respectively (p=0.504). OS from the start of BEV were 6.18 months in pts with early administration, and 6.47 in the delayed administration group (p=0.318). Toxicity profiles were similar in the 2 groups. Clinical benefit was observed in 12 out of 49 pts treated with early BEV, and in 20 out of 47 treated with delayed BEV. According to univariate analysis, KPS, MGMT methylation and time from diagnosis to start of BEV were predictors of OS in all pts, regardless of the timing of administration of BEV CONCLUSION: The results obtained in this study suggest that the delayed administration of BEV can be considered in select pts with recurrent GBM. Further prospective studies are needed to better define the best time for BEV administration in pts with recurrent GBM
- Published
- 2018
20. EP-1568 Long-term results of [18F] Fluorocholine PET/CT guided SBRT in patients with prostate cancer
- Author
-
P. Cocuzza, A. Cristaudo, A. Gonnelli, M. Cantarella, S. Montrone, Francesco Pasqualetti, Roberto Mattioni, Aldo Sainato, A. Molinari, D. Baldaccini, Roberta Zanca, Martina Sollini, P. Erba, M. Panichi, A. Marciano, and Fabiola Paiar
- Subjects
oligometastatic PCa, SBRT, ([18F]FMCH) PET/CT ,medicine.medical_specialty ,PET-CT ,SBRT ,business.industry ,oligometastatic PCa ,([18F]FMCH) PET/CT ,Hematology ,Long term results ,medicine.disease ,Prostate cancer ,Oncology ,Medicine ,Radiology, Nuclear Medicine and imaging ,In patient ,Radiology ,business ,18F-fluorocholine - Published
- 2019
21. EP-1648 Radio-chemotherapy with temozolomide in elderly patients with glioblastoma: our experience
- Author
-
A. Gonnelli, Fabiola Paiar, S. Montrone, M. Cantarella, Francesco Pasqualetti, and A. Molinari
- Subjects
Oncology ,medicine.medical_specialty ,Temozolomide ,business.industry ,radio-chemotherapy ,temozolomide ,Hematology ,medicine.disease ,elderly ,Internal medicine ,Glioblastoma,radio-chemotherapy, temozolomide, elderly ,medicine ,Radiology, Nuclear Medicine and imaging ,Glioblastoma ,business ,medicine.drug ,Radio chemotherapy - Published
- 2019
22. EP-1298: Stereotactic radiotherapy in oligometastatic patients with lung metastasis from colon-rectal cancer
- Author
-
S. Montrone, Concetta Laliscia, C. Vivaldi, Aldo Sainato, Gianluca Masi, G. Coraggio, Maria Grazia Fabrini, B. Manfredi, M. Cantarella, Francesco Pasqualetti, Fotios Loupakis, and Alfredo Falcone
- Subjects
Oncology ,Stereotactic radiotherapy ,medicine.medical_specialty ,business.industry ,Radiology Nuclear Medicine and imaging ,Internal medicine ,Lung metastasis ,medicine ,Colon rectal cancer ,Radiology, Nuclear Medicine and imaging ,Hematology ,business - Published
- 2016
- Full Text
- View/download PDF
23. EP-2092: Impact of treatment volumes in loco-regional failure of oral cancer in patients treated with IMRT
- Author
-
D. Delishaj, E. Lombardo, S. Montrone, L. Fatigante, M. Cantarella, F. Matteucci, Maria Grazia Fabrini, G. Coraggio, and Stefano Ursino
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Cancer ,Hematology ,medicine.disease ,urologic and male genital diseases ,female genital diseases and pregnancy complications ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Radiology Nuclear Medicine and imaging ,030220 oncology & carcinogenesis ,Internal medicine ,Medicine ,Radiology, Nuclear Medicine and imaging ,In patient ,business - Published
- 2016
- Full Text
- View/download PDF
24. Stereotactic body radiotherapy of bone metastases in oligometastatic disease: prognostic factors of oncologic outcomes
- Author
-
S. Montrone, Francesco Fiorica, Fabrizio Matteucci, David Fedele, Valentina Mazzotti, Riccardo Morganti, Stefano Ursino, Maria Grazia Fabrini, Paola Anna Erba, Valentina Menghini, Davide Caramella, M. Cantarella, Ursino, S, Montrone, S, Cantarella, M, Menghini, V, Matteucci, F, Mazzotti, V, Fiorica, F, Fedele, D, Erba, P, Morganti, R, Fabrini, M, and Caramella, D
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Positron emission tomography ,Stereotactic body radiotherapy ,medicine.medical_treatment ,Standardized uptake value ,Bone Neoplasms ,Radiosurgery ,Risk Assessment ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,Risk Factors ,medicine ,Humans ,Oligometastatic disease ,Survival analysis ,Aged ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,Dose fractionation ,Retrospective cohort study ,General Medicine ,Middle Aged ,Prognosis ,Survival Analysis ,Surgery ,Bone metastase ,Treatment Outcome ,Oncology ,Italy ,030220 oncology & carcinogenesis ,Predictive value of tests ,Positron-Emission Tomography ,Standard uptake value ,Female ,Radiology ,Dose Fractionation, Radiation ,business ,030217 neurology & neurosurgery - Abstract
Background To evaluate the safety of stereotactic body radiotherapy (SBRT) of bone metastases in oligometastatic disease and to investigate prognostic factors of local control (LC), progression/disease-free survival (PDFS), and overall survival (OS). Methods Eligibility criteria were number of metastates ≤5, controlled primary tumor without evidence of progression under systemic therapy, exclusion of surgery, and no previous radiotherapy of the lesion of interest. Oligometastatic status was classified into only bone (BOD) and outside bone disease (OBOD), whereas SBRT was delivered to bone lesions using 2 different schedules: 24 Gy/1 fraction or 27 Gy/3 fractions. A positron emission tomography study of the lesion of interest was performed at baseline and at 3 months after SBRT to evaluate metabolic response according to European Organization for Research and Treatment of Cancer (EORTC) criteria. A Cox regression model was used for univariate and multivariate analysis. Results Between January 2010 and December 2013, 40 patients were enrolled. Only 1 patient experienced severe late toxicity (radiation-related fracture). Local control was longer among responders’ than nonresponders’ lesions (94.2% and 91.2% versus 63% and 35% at 1 and 2 years, respectively) (p = 0.004; hazard ratio = 9.958). The multivariate analysis of PDFS showed a significant correlation with planning target volume (PTV) size (p = 0.003) and oligometastatic status (p = 0.002). The multivariate analysis of OS confirmed a statistically significant value of the oligometastatic status (p = 0.002) and a significant trend for PTV size (p = 0.065). Conclusions Stereotactic body radiotherapy is safe with a low incidence of severe toxicity. Positron emission tomography response was a strong prognostic factor of LC whereas BOD status and small PTV size could identify a subset of oligometastatic patients at better prognosis.
- Published
- 2016
25. Use of Proktis-M suppositories in patients undergoing neoadjuvant radiochemotherapy for adenocarcinoma of the rectum
- Author
-
S, Montrone, A, Gonnelli, M, Cantarella, and A, Sainato
- Subjects
Adjuvants, Immunologic ,Rectal Neoplasms ,Suppositories ,Humans ,Proctitis ,Chemoradiotherapy ,Adenocarcinoma ,Hyaluronic Acid ,Neoadjuvant Therapy - Abstract
Generally speaking, the negative side of radiation treatment of the pelvic district is the toxicity that may compromise the patient's quality of life and lead to temporary suspension of treatment with possible negative effects on its effectiveness. In neoadjuvant radiochemotherapy for locally advanced rectal cancer (LARC), the toxicity that is most frequently observed is proctitis, usually treated with topical corticosteroids or mesalazine. Hyaluronic acid's function is to restore the regular trophism and elasticity of the connective tissues leading to faster repair of the damage, and this could represent a viable option for the control of actinic proctitis.Since March 2012, a neoadjuvant radiochemotherapy protocol has been active at the Pisa Universitary Hospital for patients with LARC; 23 patients have been enrolled up to the present. Treatment involves an induction chemotherapy phase according to the FOLFOXIRI + Bevacizumab regimen for 6 cycles, followed by chemotherapy (capecitabina + Bevacizumab) concomitant with radiotherapy (5040 cGy in 28 fractions). Surgery is scheduled 6-8 weeks after the end of RTCT. During the course of associated treatment (RTCT), 12/23 patients received topical therapy with hyaluronic acid (Proktis-M suppositories) for the prevention of proctitis.All 23 patients enrolled in the study completed the induction chemotherapy phase. In the first 11 enrolled patients who did not receive prior Proktis-M suppositories, intense rectal toxicity was observed. Proctalgia of grade G1-2 and G3-4 presented respectively in 64% and 36% of cases, with consequent interruption of treatment which, in 45% of patients, lasted longer than 10 days. In the remaining 12 patients who underwent prior treatment with Proktis-M suppositories, the percentage of rectal toxicity was lower. In those cases where it did present, onset was later and its intensity and duration lower. 25% of patients did not develop proctalgia, 33% developed proctalgia of grade G1 and 42% proctalgia of grade G2. In none of these was it found necessary to interrupt radiochemotherapy.Prior topical treatment with Proktis-M suppositories in patients undergoing preoperative RTCT for LARC, enabled us to carry out radiochemotherapy at scheduled times, so protecting the treatment's effectiveness on the down-staging of the disease and preserving the patient's quality of life.
- Published
- 2015
26. PO-0630: The role of mc4r gene polymorphisms in gbm patients treated with concomitant radio-chemotherapy
- Author
-
Guido Bocci, S. Montrone, G. Coraggio, Fabiola Paiar, Paola Orlandi, Francesco Pasqualetti, S. Guarini, Vittorio Simeon, Anna Fioravanti, A. Gonnelli, T. Di Desiderio, D. Giuliani, Romano Danesi, Maria Grazia Fabrini, M. Cantarella, E. Lombardo, and D. Delishaj
- Subjects
Oncology ,business.industry ,Concomitant ,Cancer research ,Medicine ,Radiology, Nuclear Medicine and imaging ,Hematology ,business ,Gene ,Radio chemotherapy - Published
- 2017
27. P17.12 Role of XRCC1 SNP in patients with glioblastoma treated with upfront radio-chemotherapy
- Author
-
F. Carbone, Fabiola Paiar, A. Gonnelli, M. Mazzanti, M. Cantarella, Katia Zavaglia, Riccardo Morganti, G. Naccarato, A. Molinari, V. Ortensi, Sara Franceschi, and Francesco Pasqualetti
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.disease ,XRCC1 ,Text mining ,Internal medicine ,medicine ,SNP ,In patient ,Neurology (clinical) ,business ,POSTER PRESENTATIONS ,Radio chemotherapy ,Glioblastoma - Abstract
Aims: XRCC1 proteins are involved in DNA repair pathways. Given the association of XRCC1 activity and the resistance to chemo-radiotherapy, the aim of this study was to evaluate the possible predictive and therapeutic role of the XRCC1 SNPs on GBM patients treated with up front radiotherapy, alone or in combination with temozolomide. Methods: Fifty-five patients with a proven diagnosis of GBM, ECOG PS 0-2, age>18 years, and treated with radiotherapy with or without temozolomide were enrolled. Genomic DNA was extracted and XRCC1 gene SNPs were analyzed; the allelic discrimination was performed using an ABI PRISM 7900 SDS (Applied Biosystems, Carlsbad, CA, USA) and with validated TaqMan® SNP genotyping assays (Applied Biosystems). Kaplan Meier curves were performed for statistical association with genotypes. The study has been approved by the local IRB. Results: At the data analysis, the median progression-free survival (PFS) and median overall survival (OS) of these patients were 20 months and 11 months, respectively. A relevant finding of our study was the identification of a XRCC1 genotype that was significantly associated with OS: patients harboring the TT or CC genotype had 12 and 24-month OS ratio of 75 and 16%, respectively, whereas, patients with genotype TC 88 and 34%, respectively. Conclusions: The XRCC1 genotype is significantly associated with a shorter OS in GBM patients treated with radiotherapy and temozolomide schedule. The present, pilot study may represent the stimulus to prospectively investigate the role of XRCC1 polymorphisms as a predictive pharmacogenetic marker or as a target for new drug therapies for GBM patients.
- Published
- 2017
28. P01.138 Radio-chemotherapy with temozolomide in elderly patients with glioblastoma: our experience
- Author
-
P. Cocuzza, M. Cantarella, A. Gonnelli, Maria Grazia Fabrini, S. Montrone, Fabiola Paiar, A. Molinari, and Francesco Pasqualetti
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Temozolomide ,business.industry ,medicine.disease ,Poster Presentations ,Text mining ,Internal medicine ,medicine ,Neurology (clinical) ,business ,Radio chemotherapy ,medicine.drug ,Glioblastoma - Abstract
BACKGROUND: Glioblastoma multiforme (GBM) is the most aggressive brain tumor in adults and the second most common brain cancer after meningioma with a peak of incidence on the fifthy decades of life. Due to the progressive ageing of the developed country population, more than a half of new cases occurs in patients older than 65 years. The aim of the present study was to evaluate the clinical outcome of radio-chemotherapy with temozolomide in patients with glioblastoma aged more than 65 years. MATERIAL AND METHODS: Sixty-three patients treated with radiotherapy and chemotherapy at Pisa University Hospital between September 2004 and November 2017 were enrolled in this retrospective analysis. All patients had a proven diagnosis of glioblastoma grade IV WHO, ECOG PS 0–2, age ≥ 65. Radiotherapy was delivered in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy. During radiotherapy, temozolomide was administered at a dose of 75 mg per square meter of body-surface area per day from the first to the last day of radiotherapy. 5–6 weeks after the end of radiotherapy, adjuvant temozolomide was administered at 150–200 mg per square meter for five consecutive days, every 28 days. A maximum of 12 cycles were prescribed if MRI showed no disease progression and temozolomide was well tolerated. RESULTS: Data analysis was performed in April 2018. The present study was performed in 37 male and 26 female patients with a median age at diagnosis of 72,5 years (range=65–89). Fifty-seven patients underwent surgical resection, four patients stereotactic diagnostic biopsy, two patients had a radiologic diagnosis only. During follow up, we recorded 46 cases of disease progression with a median progression-free survival (PFS) of 12 months (range 1–88 months). Median overall survival (OS) were 25 months (range 1–107 months); at data analysis, 65 patients were died. After disease recurrence, based on ECOG, tumor burden and age, patients were treated with surgery (15 cases), chemotherapy (30 cases) and re-irradiation (11 cases). CONCLUSION: In our experience, progression free survival and overall survival were similar to those reported in literature for younger patients. We think that radiochemotherapy is a good option for older patients with a good performance status in glioblastoma treatment.
- Published
- 2018
29. EP-1129: Perfusion CT in the evaluation of Nodal response after RCT in H&N cancers: a prospective study
- Author
-
A. Cristaudo, D. Baldaccini, Davide Caramella, E. Calistri, M. Cantarella, A. Gonnelli, F. Matteucci, L. Faggioni, P. Ferrazza, E. Lombardo, Fabiola Paiar, R. Mattioli, A. Molinari, Riccardo Morganti, D. Delishaj, S. Montrone, Stefano Ursino, F. Orlandi, and Francesco Pasqualetti
- Subjects
Oncology ,Randomized controlled trial ,law ,business.industry ,Medicine ,Radiology, Nuclear Medicine and imaging ,Hematology ,NODAL ,Nuclear medicine ,business ,Prospective cohort study ,Perfusion ,law.invention - Published
- 2018
30. EP-2288: Role of circulating DNA in Glioblatoma IDH1 wild type patients suitable for radiotherapy
- Author
-
A. Molinari, Giuliana Restante, Eleonora Rofi, D. Delishaj, M. Del Re, M. Cantarella, Fabiola Paiar, S. Montrone, A. Gonnelli, and Francesco Pasqualetti
- Subjects
Radiation therapy ,IDH1 ,Oncology ,business.industry ,medicine.medical_treatment ,Cancer research ,Wild type ,Medicine ,Circulating DNA ,Radiology, Nuclear Medicine and imaging ,Hematology ,business - Published
- 2018
31. EP-1497: Predictive factors of nodal response to neoadjuvant RTCT in pts affected by LARC
- Author
-
A. Cristaudo, A. Gonnelli, M. Cantarella, Stefano Ursino, D. Baldaccini, Fabiola Paiar, F. Orlandi, Concetta Laliscia, Aldo Sainato, B. Manfredi, Riccardo Morganti, S. Montrone, and Francesco Pasqualetti
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Internal medicine ,medicine ,Radiology, Nuclear Medicine and imaging ,Hematology ,NODAL ,business - Published
- 2018
32. EP-1384: The role of SABR for eradicative treatment of thymoma recurrences
- Author
-
E. Lombardo, G. Pastore, A. Chella, J. Petrini, C. Menichelli, A. Fanelli, M. Cantarella, C. Casamassima, and V. Mazzotti
- Subjects
medicine.medical_specialty ,Thymoma ,Oncology ,business.industry ,medicine ,Radiology, Nuclear Medicine and imaging ,Hematology ,Radiology ,medicine.disease ,business ,SABR volatility model - Published
- 2018
33. Protein Disulfide Stress: Proposed Radical‐Free Bridges to Neurodegeneration
- Author
-
Timothy D. Foley, Paul F. Gillespie, Shayne Wierbowski, and Kristen M. Cantarella
- Subjects
Stress (mechanics) ,Chemistry ,Neurodegeneration ,Genetics ,medicine ,Disulfide bond ,Biophysics ,medicine.disease ,Molecular Biology ,Biochemistry ,Biotechnology - Published
- 2015
34. PO-0756: Choline PET/CT and Stereotactic Body Radiotherapy in oligometastatic prostate cancer patients
- Author
-
D. Delishaj, M. Cantarella, S. Montrone, Carlo Greco, L. Derosa, A. Cristaudo, P. Erba, P. Cocuzza, P. Ferrazza, G. Coraggio, M. Panichi, Francesco Pasqualetti, F. Matteucci, Aldo Sainato, and Maria Grazia Fabrini
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,business.industry ,Hematology ,Choline pet ct ,medicine.disease ,03 medical and health sciences ,Prostate cancer ,030104 developmental biology ,0302 clinical medicine ,Radiology Nuclear Medicine and imaging ,030220 oncology & carcinogenesis ,Internal medicine ,Medicine ,Radiology, Nuclear Medicine and imaging ,business ,Nuclear medicine ,Stereotactic body radiotherapy - Published
- 2016
- Full Text
- View/download PDF
35. The analytic hierarchy process as a systematic approach to the identification of important parameters for the reliability assessment of passive systems
- Author
-
Antonio Cammi, Enrico Zio, and M Cantarella
- Subjects
Nuclear and High Energy Physics ,Engineering ,Passive systems ,business.industry ,Mechanical Engineering ,Analytic hierarchy process ,law.invention ,Reliability engineering ,Identification (information) ,Systems analysis ,Nuclear Energy and Engineering ,law ,Safety engineering ,Nuclear power plant ,Forensic engineering ,Decomposition (computer science) ,General Materials Science ,Safety, Risk, Reliability and Quality ,business ,Waste Management and Disposal ,Reliability (statistics) - Abstract
Passive systems play a crucial role in the development of future solutions for nuclear plant technology. A fundamental issue still to be resolved is the quantification of the reliability of such systems. In this paper, we firstly illustrate a systematic methodology to guide the definition of the failure criteria of a passive system and the evaluation of its probability of occurrence, through the identification of the relevant system parameters and the propagation of their associated uncertainties. Within this methodology, we propose the use of the analytic hierarchy process as a structured and reproducible tool for the decomposition of the problem and the identification of the dominant system parameters. An example of its application to a real passive system is illustrated in details.
- Published
- 2003
36. PO-0665: The role of post-mastectomy radiotherapy (PMRT) and prognostic factors of locoregional recurrence
- Author
-
F. Orlandi, Riccardo Morganti, L. Fatigante, B. Manfredi, V. Mazzotti, D. Delishaj, Davide Caramella, S. Spagnesi, F. Matteucci, M. Pnichi, Maria Grazia Fabrini, A. Gonnelli, Stefano Ursino, Fabiola Paiar, Francesco Pasqualetti, A. Cristaudo, Aldo Sainato, A. Molinari, M. Roncella, Concetta Laliscia, Alfredo Falcone, D. Baldaccini, M. Cantarella, and E. Lombardo
- Subjects
medicine.medical_specialty ,Oncology ,business.industry ,Medicine ,Radiology, Nuclear Medicine and imaging ,Hematology ,Radiology ,business ,Post mastectomy radiotherapy - Published
- 2017
37. EP-1275: Patients with locally advanced rectal cancer (larc): predictive factors of pathological response
- Author
-
C. Vivaldi, M. Cantarella, Piero Buccianti, Concetta Laliscia, Francesco Pasqualetti, Fabiola Paiar, Aldo Sainato, B. Manfredi, Gianna Musettini, Riccardo Morganti, S. Montrone, A. Gonnelli, Gianluca Masi, and G. Coraggio
- Subjects
Oncology ,medicine.medical_specialty ,Colorectal cancer ,business.industry ,Internal medicine ,medicine ,Locally advanced ,Radiology, Nuclear Medicine and imaging ,Pathological response ,Hematology ,medicine.disease ,business - Published
- 2017
38. Protein vicinal thiol oxidations in the healthy brain: not so radical links between physiological oxidative stress and neural cell activities
- Author
-
Paul F. Gillespie, Timothy D. Foley, Kristen M. Cantarella, and Edward S. Stredny
- Subjects
Free Radicals ,Proteome ,Oxidative phosphorylation ,Neurotransmission ,medicine.disease_cause ,Biochemistry ,Redox ,Rats, Sprague-Dawley ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,Stress, Physiological ,medicine ,Animals ,Sulfhydryl Compounds ,Cytoskeleton ,chemistry.chemical_classification ,Neurons ,Chemistry ,Brain ,General Medicine ,Glutathione ,Oxidative Stress ,Thiol ,Oxidation-Reduction ,Oxidative stress - Abstract
Reversible oxidations of protein thiols have emerged as alternatives to free radical-mediated oxidative damage with which to consider the impacts of oxidative stress on cellular activities but the scope and pathways of such oxidations in tissues, including the brain, have yet to be fully defined. We report here a characterization of reversible oxidations of glutathione and protein thiols in extracts from rat brains, from two sources, which had been (1) frozen quickly after euthanasia to preserve in vivo redox states and (2) subjected to alkylation upon tissue disruption to trap reduced thiols. Brains were defined, relatively, as Reduced and Moderately Oxidized based on measured ratios of reduced (GSH) to oxidized (GSSG) glutathione. Levels of protein disulfides formed by the cross-linking of closely-spaced (vicinal) protein thiols, but not protein S-glutathionylation, were higher in extracts from the Moderately Oxidized brains compared to the Reduced brains. Moreover, the oxidized vicinal thiol proteome contains proteins that impact cellular energetics, signaling, neurotransmission, and cytoskeletal dynamics among others. These findings argue that kinetically-competent pathways for reversible, two-electron oxidations, of protein vicinal thiols can be activated in healthy brains in response to physiological oxidative stresses. We propose that such oxidations may link oxidative stress to adaptive, but also potentially deleterious, changes in neural cell activities in otherwise healthy brains.
- Published
- 2014
39. Study of Michaelis-Menten kinetics with linear-type product inhibition in ultrafiltration membrane reactors: Mathematical model, experimental and data
- Author
-
M. Cantarella, A. Gallifuoco, and Francesco Alfani
- Subjects
Chromatography ,Membrane reactor ,Mathematical Models ,Chemistry ,Kinetics ,General Engineering ,Ultrafiltration ,Thermodynamics ,Michaelis–Menten kinetics ,Enzymes ,Enzyme catalysis ,Membrane ,Product inhibition ,Biochemical Engineering ,Chemical Reactors ,By-product - Abstract
A method is proposed for the study of enzymatic reactions affected by product inhibition. The use of continuous and stirred ultrafiltration membrane re A mathematical model has been defined which depicts Michaelis-Menten kinetics with a linear-type product inhibition for all competitive, non-competitiv The experimental procedure needed to identify the inhibition pattern and to evaluate the set of kinetic constants is detailed. Two model systems, the h
- Published
- 1990
40. 2042 Preoperative short course radiotherapy in elderly patients (^75 years) affected by locally advanced rectal cancer
- Author
-
Francesco Pasqualetti, E. Lombardo, Piero Buccianti, G. Coraggio, D. Delishaj, B. Manfredi, S. Montrone, Aldo Sainato, Riccardo Balestri, M. Cantarella, and C. Laliscia
- Subjects
Cancer Research ,medicine.medical_specialty ,Oncology ,business.industry ,Colorectal cancer ,Locally advanced ,Medicine ,Radiology ,business ,medicine.disease ,Short course radiotherapy - Published
- 2015
41. 2918 Preliminary experiences of second surgery combined with postoperative systemic therapy in patients with recurrent Glioblastoma
- Author
-
A. Cristaudo, D. Caramella, L. Fatigante, Maria Grazia Fabrini, A. Gonnelli, F. Matteucci, S. Ursino, M. Cosottini, A. Weiss, Francesco Pasqualetti, R. Vannozzi, M. Cantarella, P. Perrini, and D. Delishaj
- Subjects
Cancer Research ,medicine.medical_specialty ,Oncology ,business.industry ,Recurrent glioblastoma ,medicine ,In patient ,business ,Systemic therapy ,Surgery - Published
- 2015
42. 2736 Stereotactic Body Radiotherapy (SBRT) in oligometastatic gynecological cancer
- Author
-
Maria Grazia Fabrini, S. Montrone, D. Delishaj, E. Lombardo, C. Laliscia, M. Cantarella, R. Morganti, and G. Coraggio
- Subjects
Cancer Research ,medicine.medical_specialty ,Oncology ,business.industry ,Medicine ,Radiology ,business ,Gynecological cancer ,Stereotactic body radiotherapy - Published
- 2015
43. 2255 Safety and effectiveness of the combination of single chemotherapeutic agent (gemcitabine) with radiotherapy in radically resected pancreatic adenocarcinoma
- Author
-
P. Cocuzza, Aldo Sainato, S. Montrone, N.L.V. Cernusco, M. Cantarella, Ugo Boggi, Alfredo Falcone, Francesco Pasqualetti, M. Coppola, V. Mazzotti, P. Ferrazza, Enrico Vasile, and R. Morganti
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,medicine.disease ,Gemcitabine ,Radiation therapy ,Internal medicine ,medicine ,Adenocarcinoma ,business ,medicine.drug - Published
- 2015
44. 3316 Non-melanoma skin cancer treated with HDR Brachytherapy and Valencia applicator in elderly patients
- Author
-
G. Coraggio, Francesco Pasqualetti, Francesco Perrone, E. Lombardo, Maria Grazia Fabrini, S. Ursino, S. Montrone, M. Cantarella, P. Cocuzza, D. Delishaj, C. Laliscia, and B. Manfredi
- Subjects
Cancer Research ,medicine.medical_specialty ,Oncology ,business.industry ,medicine.medical_treatment ,Brachytherapy ,Medicine ,Skin cancer ,business ,medicine.disease ,Surgery ,Non melanoma - Published
- 2015
45. Membrane reactors for the investigation of product inhibition on enzyme activity
- Author
-
Laura Cantarella, Francesco Alfani, A Gallifuoco, and M. Cantarella
- Subjects
Chromatography ,biology ,Membrane reactor ,Chemistry ,Ultrafiltration ,Filtration and Separation ,Cellobiose ,Biochemistry ,Enzyme assay ,Hydrolysis ,chemistry.chemical_compound ,Membrane ,Product inhibition ,biology.protein ,General Materials Science ,Enzyme kinetics ,Physical and Theoretical Chemistry - Abstract
The use of ultrafiltration cells as membrane reactors is extended to the study of enzyme kinetics with product inhibition. This reactor configuration allows the lack of accuracy and instrument limitations typical of differential analysis and of time-course data analysis for experiments performed in batch reactors to be overcome. The hydrolysis of cellobiose to glucose, catalysed by β-glucosidase from Aspergillus niger (E.C. 3.2.1.4), was chosen as model system. The activity of this enzyme is suppressed by glucose according to a mixed-type inhibition pattern. Attention was paid to the possibility of determining the presence of either reversible or irreversible product inhibition. Details of the apparatus, experimental procedure and data correlation are given. Phenomena such as thermal deactivation, mechanical stress by shear and membraneto-enzyme affinity could alter the system response and mask the effects of inhibition.
- Published
- 1990
46. Product inhibition studies in membrane reactors
- Author
-
A Gallifuoco, Francesco Alfani, M. Cantarella, and Laura Cantarella
- Subjects
enzyme immobilization ,enzyme inhibition ,membrane reactor ,History and Philosophy of Science ,Membrane reactor ,Chemical engineering ,Chemistry ,Product inhibition ,General Neuroscience ,General Biochemistry, Genetics and Molecular Biology - Published
- 1990
47. Apple, Evaluation of Experimental Miticides, 1991
- Author
-
D. F. Polk, F. C. Swift, and M. Cantarella
- Abstract
Treatments were applied to 7 tree plots replicated 4 times in a randomized complete block design. The orchard block consisted of 'Empire', 'Red Delicious', and 'Rome' on M7a, planted in 1982 on a 15 by 18 ft spacing. Replicates 1 and 2 were on 'Red Delicious', while replicates 3 and 4 were on 'Empire'. Sprays were applied with an FMC handgun sprayer using a 5 HP diaphragm pump at 280 psi until run off, with approx. 4 gal of spray applied to each tree. One application of Pydrin 2.4 EC 178 ml/100 gal was made on 6 Jun in order to build mite populations, since few mites were present early in the season. Miticides were applied on 1 Jul and again on 10 Jul. Conditions during applications were 75°F on both dates, with 2 mph winds and cloudy skies on 1 Jul, and 2-4 mph winds and clear skies on 10 Jul. Treatments were as follows: 1) BAS 300 00 I 20 WP .05 lb AI/100 gal, 2) BAS 300 00 I 20 WP . 12 lb AI/100 gal, 3) BAS 300 11 I 75 WP .05 lb AI/100 gal, 4) BAS 300 11 I 75 WP . 12 lb AI/100 gal, 5) Omite (propargite) 30 WP .60 lb AI/100 gal, and 6) Omite 30 WP .30 lb AI/100 gal, 7) Untreated. ERM counts were taken in samples of 15 leaves per tree on 7 Jun (pre-treatment), and again on 3, 8, 15, 22, 29 Jul, and 5, 12 Aug. SP populations were evaluated on 12 Aug. Predacious mites and beetles were not present early in the season, since they had been eliminated by the Pydrin application. Fruit finish was evaluated by taking 30 fruit from each tree and evaluating for fruit russet on a 0 to 5 basis. Values were used as follows: 0 = no russet, 1 = raised lenticels, 2 = 1-10% russeted, 3 = 11-15% russeted, 4 = 16-50% russeted, and 5 = >51% russeted. Each fruit was evaluated, and an average per replicate was used in the calculations.
- Published
- 1992
48. Apple, Evaluation of Experimental Insecticide Ac-303630 24 Sc, 1991
- Author
-
D. F. Polk, F. C. Swift, and M. Cantarella
- Abstract
Treatments were applied to 5 tree plots replicated 4 times in a randomized complete block design. The orchard block consisted of'Red Delicious' on Mill planted in 1970 on a 20' by 20' spacing. Sprays were applied with an FMC handgun sprayer using a 5 HP diaphragm pump at 280 psi until run off, with approx. 4 gal of spray applied to each tree. There were 5 treatments in this test; 1) = AC-303630 50.9 g AI/100 gal, 2) = AC-303630 101.8 g AI/100 gal, 3) = AC-303630 203.7 g AI/100 gal, 4) = Standard Program, and 5) = untreated control. The Standard Program consisted of: Pink—Thiodan 50 WP 454 g/100 gal, Petal Fall—Imidan 50 WP 454 g/100 gal + Carzol 92 SP 60 g/ 100 gal, 1st Cover—Imidan 454 g/100 gal, 2nd Cover—Imidan 454 g/100 gal + Lannate 1.8 L 235 ml/100 gal, 3rd Cover—Imidan 454 g/100 gal, 4th Cover— Imidan 454 g/100 gal, 5th Cover—Imidan 454 g/100 gal, and 6th Cover—Imidan 454 g/100 gal. Spray dates for all treatments and conditions were: Pink— 12 Apr 57°F, 2 mph wind & clear, Petal Fall—2 May 62°F, 0-2 mph wind & clear, 1st Cover—20 May 65°F, 0-2 mph wind & clear, 2nd Cover—10 Jun 85°F, 5 mph wind & clear, 3rd Cover—1 Jul 75°F 0-2 mph wind & cloudy, 4th Cover—17 Jul 83°F, 5 mph wind & clear, 5th Cover—6 Aug 75°F, 2-3 mph wind & clear, and 6th Cover—28 Aug 75°F, 0-2 mph wind & clear. All treatments received regular fungicide cover sprays of Captan or Captan + Rubigan. Mite and mite predator counts were done on a weekly basis, with each mite sample consisting of 25 leaves per tree, brushed and counted with a binocular scope. SP counts are reported as a 3 min count per tree. SJS counts were done on 1 Aug, and reported as the number damaged per 100 fruit per tree and as the number of sites present in the 20 maximally infested fruit per tree. AA counts were made on 6 Jun and 14 Jun. Data are reported as average aphis per colony of the 10 maximally infested colonies per tree. STLM, WALH, EAS, and RAA counts were done on 21 May. STLM counts are reported as mines per 3 min count per tree. WALH counts are reported as damaged leaves out of 300 leaves per tree. EAS counts are reported as infestations per 300 fruit. RAA counts are reported as colonies per tree. A post-harvest fruit evaluation was done, using 100 fruit per tree and reported as percent damage by AM, CM, EAS, PC, SJS, TABM/LR, and TPB. A postharvest fruit finish evaluation consisted of 30 fruit per tree. Each fruit was rated on a 0 to 5 scale for percent russet. Values used were as follows: 0 = no russet, I = raised lenticels, 2 = 1-10% russeted, 3 = 11-15% russeted, 4 = 16-50% russeted, and 5 = >51% russeted. Mean values of each replicate were used for calculations. Data were transformed to log(x + 1) for analysis at P = 0.01 except on the 15 Jul mite count where P = 0.05.
- Published
- 1992
49. Kinetic studies of polymers bearing grafted enzymes in solution and gelified as a membrane
- Author
-
D. Thomas, M. Cantarella, and J. Wetzer
- Subjects
chemistry.chemical_classification ,biology ,Diffusion ,General Engineering ,Synthetic membrane ,Chemical modification ,Substrate (chemistry) ,Polymer ,Catalysis ,Membrane ,chemistry ,Chemical engineering ,biology.protein ,Organic chemistry ,Ribonuclease - Abstract
Soluble polymers bearing ribonuclease have been produced by a co- crosslinking method. The kinetic properties have been studied with the polymer in solution and gelified as a membrane, and the effects of chemical modification and of insolubilization studied separately. The results obtained have been compared with those generated by native enzyme and ribonuclease immobilized within an artificial membrane. Experiments have been performed with a high molecular weight substrate (RNA) and a low molecular weight substrate (cytidine-2′, 3′-phosphate). With the data obtained using these substrates, it is possible to evaluate the effects of the diffusion and accessibility constraints on the kinetic behavior of the enzyme.
- Published
- 1978
50. Inhibition of ?-amylase purified fromOctopus vulgaris Lam. by albumin inhibitors from wheat flour
- Author
-
V. Silano, V. Buonocore, M. A. Belisario, V. Scardi, and M. Cantarella
- Subjects
Chromatography ,biology ,Proteinase inhibitor ,Albumin ,Wheat flour ,Medicine (miscellaneous) ,Plant physiology ,Plant Science ,Polypeptide chain ,chemistry.chemical_compound ,Monomer ,Biochemistry ,Affinity chromatography ,chemistry ,Chemistry (miscellaneous) ,biology.protein ,Amylase ,Food Science - Abstract
Octopus α-amylase has been purified to homogeneity by single-step affinity chromatography on Sepharose-bound wheat albumin inhibitors. Two electrophoretically distinguishable isoamylases are obtained, both consisting of a single polypeptide chain with molecular weight 45,000. Octopus α-amylase is more effectively inhibited by a monomeric than by a dimeric protein inhibitor from wheat. The inhibition is dependent on pH, temperature, and time of preincubation. Properties are compared with those of other animal α-amylases.
- Published
- 1981
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.